Immunological mechanisms underlying clinical phenotypes and noninvasive diagnosis of immune checkpoint inhibitor-induced kidney disease
Open accessAbstract
Summary: Immune checkpoint inhibitors (ICIs) have become a mainstay of cancer therapy, with over 80 FDA‐approved indications. Used in a variety of settings and in combination with each other and with traditional chemotherapies, the hyperactive immune response induced by ICIs can often lead to immune‐related adverse events in bystander normal tissues such as the kidneys, lungs, and the heart. In the kidneys, this immune‐related adverse event manifests as acute interstitial nephritis (ICI‐AIN). In the era of widespread ICI use, it becomes vital to understand the clinical manifestations of ICI‐AIN and the importance of prompt diagnosis and management of these complications. In this review, we delve into the clinical phenotypes of ICI‐AIN and how they differ from traditional drug‐induced AIN. We also detail what is known about the mechanistic underpinnings of ICI‐AIN and the important diagnostic and therapeutic implications behind harnessing those mechanisms to further our understanding of these events and to formulate effective treatment plans to manage ICI‐AIN.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · see citing works
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713 · see citing works
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088 · see citing works
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955 · see citing works
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914 · see citing works
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · see citing works
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
Cabrita, R., Lauss, M., Sanna, A., Donia, M., Skaarup Larsen, M., Mitra, S., Johansson, I., Phung, B., Harbst, K., Vallon-Christersson, J., et al. (2020) · Nature · doi:10.1038/s41586-019-1914-8 · Cited by 2,374 · see citing works
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314 · see citing works
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868 · see citing works
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860 · see citing works
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689 · see citing works
Immune-related adverse events of checkpoint inhibitors
Ramos‐Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N. M., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suarez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,447 · see citing works
Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161 · see citing works
Immune-checkpoint inhibitors: long-term implications of toxicity
Johnson, D. B., Nebhan, C. A., Moslehi, J. J., & Balko, J. M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00600-w · Cited by 982 · see citing works
Khoja, L., Day, D., Chen, T. W., Siu, L. L., & Hansen, A. R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx286 · Cited by 937 · see citing works
Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., Gerber, D. E., Hamad, L., Hansen, E., Johnson, D. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002435 · Cited by 917 · see citing works
Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations
Schubert, D., Bode, C., Kenefeck, R., Hou, T. Z., Wing, J. B., Kennedy, A., Bulashevska, A., Petersen, B., Schäffer, A. A., Grüning, B. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3746 · Cited by 836 · see citing works
Lo, B., Zhang, K., Lü, W., Zheng, L., Zhang, Q., Kanellopoulou, C., Zhang, Y., Liu, Z., Fritz, J. M., Marsh, R. A., et al. (2015) · Science · doi:10.1126/science.aaa1663 · Cited by 678 · see citing works
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Twomey, J. D., & Zhang, B. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00574-0 · Cited by 668 · see citing works
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
Cortazar, F. B., Marrone, K. A., Troxell, M. L., Ralto, K. M., Hoenig, M. P., Brahmer, J. R., Le, D. T., Lipson, E. J., Glezerman, I. G., Wolchok, J. D., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.04.008 · Cited by 649 · see citing works
Reversal of the TCR Stop Signal by CTLA-4
Schneider, H., Downey, J., Smith, A. M., Zinselmeyer, B. H., Rush, C. M., Brewer, J. M., Wei, B. K., Hogg, N., Garside, P., & Rudd, C. E. (2006) · Science · doi:10.1126/science.1131078 · Cited by 621 · see citing works
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
Dolladille, C., Éderhy, S., Sassier, M., Cautela, J., Thuny, F., Cohen, A. A., Fédrizzi, S., Chrétien, B., Silva, A. D., Plane, A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0726 · Cited by 592 · see citing works
Praga, M., & González, E. (2010) · Kidney International · doi:10.1038/ki.2010.89 · Cited by 507 · see citing works
Shankar, B., Zhang, J., Naqash, A. R., Forde, P. M., Feliciano, J. L., Marrone, K. A., Ettinger, D. S., Hann, C. L., Brahmer, J. R., Ricciuti, B., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.5012 · Cited by 477 · see citing works
Bleeding Complications of Native Kidney Biopsy: A Systematic Review and Meta-analysis
Corapi, K. M., Chen, J. L. T., Balk, E. M., et al. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.02.330 · Cited by 448 · see citing works
Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis
Salem, J.-E., Allenbach, Y., Vozy, A., Brechot, N., Johnson, D. B., Moslehi, J. J., & Kerneis, M. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1901677 · Cited by 443 · see citing works
Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects
Schwab, C., Gabrysch, A., Olbrich, P., Patiño, V., Warnatz, K., Wolff, D., Hoshino, A., Kobayashi, M., Imai, K., Takagi, M., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.02.055 · Cited by 441 · see citing works
CTLA-4-Mediated Inhibition of Early Events of T Cell Proliferation
Brunner-Weinzierl, M. C., Chambers, C. A., Chan, F. K.-M., Hanke, J., Winoto, A., & Allison, J. P. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.5813 · Cited by 419 · see citing works
Binding of phosphatidyl-inositol-3-OH kinase to CD28 is required for T-cell signalling
Pagès, F., Ragueneau, M., Rottapel, R. K., Truneh, A., Nunès, J. A., Imbert, J., & Olive, D. (1994) · Nature · doi:10.1038/369327a0 · Cited by 399 · see citing works
Hiraoka, N., Ino, Y., Yamazaki–Itoh, R., Kanai, Y., Kosuge, T., & Shimada, K. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.145 · Cited by 364 · see citing works
Seethapathy, H. S., Zhao, S. J., Chute, D. F., Zubiri, L., Oppong, Y. D., Strohbehn, I. A., Cortazar, F. B., Leaf, D. E., Mooradian, M. J., Villani, A., et al. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00990119 · Cited by 303 · see citing works
Self-citationMamlouk, O., Selamet, U., Machado, S., Abdelrahim, M., Glass, W. F., Tchakarov, A. S., Gaber, L. W., Lahoti, A., Workeneh, B., Chen, S., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0478-8 · Cited by 298 · see citing works
Acute kidney injury in patients treated with immune checkpoint inhibitors
Gupta, S., Short, S., Sise, M. E., Prosek, J. M., Madhavan, S. M., Soler, M. J., Ostermann, M., Herrmann, S. M., Abudayyeh, A., Anand, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003467 · Cited by 239 · see citing works
Self-citationMeraz-Muñoz, A., Amir, E., Ng, P., Ávila-Casado, C., Ragobar, C., Chan, C. T., Kim, S. J., Wald, R., & Kitchlu, A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000467 · Cited by 194 · see citing works
Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?
Perazella, M. A., & Shirali, A. C. (2019) · Kidney International · doi:10.1016/j.kint.2019.07.022 · Cited by 173 · see citing works
A Systematic Review of Immune Checkpoint Inhibitor–Associated Glomerular Disease
Kitchlu, A., Jhaveri, K. D., Wadhwani, S., Deshpande, P. P., Harel, Z., Kishibe, T., Henriksen, K., & Wanchoo, R. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.10.002 · Cited by 163 · see citing works
Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis
Moledina, D. G., Wilson, F. P., Pober, J. S., Perazella, M. A., Singh, N., Luciano, R. L., Obeid, W., Lin, H., Kuperman, M., Moeckel, G. W., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127456 · Cited by 154 · see citing works
Núñez, N. G., Berner, F., Friebel, E., Unger, S., Wyss, N., Gómez, J. M. M., Purde, M.-T., Niederer, R., Porsch, M., Lichtensteiger, C., et al. (2023) · Med · doi:10.1016/j.medj.2022.12.007 · Cited by 134 · see citing works
Isik, B., Alexander, M. P., Manohar, S., Vaughan, L. E., Kottschade, L. A., Markovic, S. N., Lieske, J. C., Kukla, A., Leung, N., & Herrmann, S. M. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.01.013 · Cited by 118 · see citing works
Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child
Ogishi, M., Yang, R., Aytekin, C., Langlais, D., Bourgey, M., Khan, T., Ali, F. A., Rahman, M., Delmonte, O. M., Chrabieh, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01388-5 · Cited by 117 · see citing works
Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies
Trüb, M., & Zippelius, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674565 · Cited by 84 · see citing works
Schulz, T. U., Zierold, S., Sachse, M., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.08.029 · Cited by 77 · see citing works
Shimozaki, K., Sukawa, Y., Beppu, N., Kurihara, I., Suzuki, S., Mizuno, R., Funakoshi, T., Ikemura, S., Tsugaru, K., Togasaki, K., et al. (2020) · Cancer Management and Research · doi:10.2147/cmar.s247554 · Cited by 75 · see citing works
Pálsson, R., Short, S., Kibbelaar, Z. A., et al. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.01.012 · Cited by 73 · see citing works
Nigro, O., Pinotti, G., Galitiis, F. D., Pietro, F. R. D., Giusti, R., Filetti, M., Bersanelli, M., Lazzarin, A., Bordi, P., Catino, A., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.04.025 · Cited by 72 · see citing works
Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study
Espi, M., Teuma, C., Novel-Catin, E., Maillet, D., Souquet, P. J., Dalle, S., Koppe, L., & Fouque, D. P. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.005 · Cited by 72 · see citing works
Seethapathy, H. S., Zhao, S. J., Strohbehn, I. A., Lee, M. D., Chute, D. F., Bates, H., Molina, G. E., Zubiri, L., Gupta, S., Motwani, S. S., et al. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.07.011 · Cited by 69 · see citing works
Self-citationLin, J. S., Mamlouk, O., Selamet, U., Tchakarov, A. S., Glass, W. F., Sheth, R. A., Layman, R. M., Dadu, R., Abdel‐Wahab, N., Abdelrahim, M., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1877415 · Cited by 66 · see citing works
Zhang, N., Qu, F., Liu, H., Li, Z., Zhang, Y., Han, X., Zhu, Z., & Lv, Y. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02242-x · Cited by 63 · see citing works
Lutgens, E., & Seijkens, T. T. P. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000300 · Cited by 61 · see citing works
Tang, J., Ramis‐Cabrer, D., Curull, V., Wang, X., Mateu-Jiménez, M., Pijuán, L., Durán, X., Qin, L., Rodríguez-Fuster, A., Aguiló, R., et al. (2020) · Cancers · doi:10.3390/cancers12092644 · Cited by 61 · see citing works
Sise, M. E., Seethapathy, H. S., & Reynolds, K. L. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0764 · Cited by 55 · see citing works
Self-citationQualls, D. A., Seethapathy, H. S., Bates, H., Tajmir, S., Heidari, P., Endres, P., Reynolds, K. L., Lawrence, D. P., & Sise, M. E. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0820-9 · Cited by 52 · see citing works
Self-citationAbdelrahim, M., Mamlouk, O., Lin, H. Y., Lin, J. S., Page, V. D., Abdel‐Wahab, N., Swan, J. T., Selamet, U., Yee, C., Diab, A. K., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1927313 · Cited by 51 · see citing works
Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
Sise, M. E., Wang, Q., Seethapathy, H. S., Moreno, D., Harden, D., Smith, R. N., Rosales, I. A., Colvin, R. B., Chute, S., Cornell, L. D., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006222 · Cited by 50 · see citing works
Self-citationSingh, S., Long, J. P., Tchakarov, A. S., Dong, Y., Yee, C., & Lin, J. S. (2022) · JCI Insight · doi:10.1172/jci.insight.165108 · Cited by 43 · see citing works
Gupta, S., García-Carro, C., Prosek, J. M., Glezerman, I. G., Herrmann, S. M., García, P., Abudayyeh, A., Lumlertgul, N., Malik, A. B., Loew, S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005646 · Cited by 39 · see citing works
Self-citationChute, D. F., Zhao, S. J., Strohbehn, I. A., Rusibamayila, N., Seethapathy, H. S., Lee, M. D., Zubiri, L., Gupta, S., Leaf, D. E., Rahma, O. E., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.05.012 · Cited by 34 · see citing works
Self-citationHultin, S., Nahar, K. J., Menzies, A. M., Long, G. V., Fernando, S. L., Atkinson, V. G., Cebon, J. S., & Wong, M. G. (2020) · BMC Nephrology · doi:10.1186/s12882-020-02044-9 · Cited by 33 · see citing works
Adam, B., Murakami, N., Reid, G., Du, K., Jasim, R., Boils, C. L., Bu, L., Hill, P. D., Murray, A. G., Renaudin, K., et al. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00920121 · Cited by 32 · see citing works
Liu, X., Wu, W., Fang, L., Liu, Y., & Chen, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.922782 · Cited by 32 · see citing works
Non-invasive Detection of Immunotherapy-Induced Adverse Events
Ferreira, C. A., Heidari, P., Ataeinia, B., Sinevici, N., Sise, M. E., Colvin, R. B., Wehrenberg-Klee, E. P., & Mahmood, U. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4641 · Cited by 24 · see citing works
Self-citationPerazella, M. A., & Sprangers, B. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab052 · Cited by 16 · see citing works
Heybeli, C., Nathan, M. A., & Herrmann, S. M. (2020) · Journal of Onco-Nephrology · doi:10.1177/2399369320945724 · Cited by 11 · see citing works
Jessel, S., Austin, M., & Kluger, H. M. (2021) · PubMed · Cited by 11 · see citing works
Differentiating Acute Interstitial Nephritis From Immune Checkpoint Inhibitors From Other Causes
Casals, J., Acosta, Y., Caballero, G., Morantes, L., Zamora, C. A., Xipell, M., Viladot, M., Guillén, E., Piñeiro, G. J., Blasco, M., et al. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.12.017 · Cited by 11 · see citing works
Gutgarts, V., & Glezerman, I. G. (2020) · Kidney360 · doi:10.34067/kid.0000132020 · Cited by 10 · see citing works
Shimozaki, K., Sukawa, Y., Beppu, N., Kurihara, I., Suzuki, S., Mizuno, R., Funakoshi, T., Ikemura, S., Tsugaru, K., Togasaki, K., et al. (2020) · doi:10.21203/rs.2.21095/v1 · Cited by 7 · see citing works
Wang, Q., Strohbehn, I. A., Zhao, S. J., Seethapathy, H. S., Strohbehn, S. D., Hanna, P. E., Lee, M. D., Fadden, R. M., Sullivan, R. J., Boland, G. M., et al. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.08.030 · Cited by 4 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- [2]2. Chute DF, Zhao S, Strohbehn IA, et al. Incidence and predictors of CKD and estimated GFR decline in patients receiving immune checkpoint inhibitors. Am J Kidney Dis. 2022;79:134-137. [PubMed: 34174363]
- [14]14. Gupta S, Short SAP, Sise ME, et al. Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021;9:e003467. [PubMed: 34625513]
Cited by
Sorted by citations
Miao, J., Thongprayoon, C., Krisanapan, P., Buglioni, A., Craici, I. M., & Cheungpasitporn, W. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.09.026 · Cited by 18 · see citing works
- Authors
- Seethapathy, H., Mistry, K., & Sise, M. E.
- Affiliations
- Harvard University (US)
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Sise, Meghan E.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2023-07-21
- Volume
- 318
- Issue
- 1
- Pages
- 61-69
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- PMC
- PMC10865966
- OpenAlex
- W4385074405
- Cited by
- 15
- References
- 73
- Citations by year
- 2026: 8 · 2025: 1 · 2024: 5 · 2023: 1
- FWCI
- 0.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Immunological Reviews (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK130839)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Keywords
- immune checkpoint inhibitors, immune-related adverse events, acute interstitial nephritis, kidney disease, drug-induced interstitial nephritis, non-invasive diagnosis, clinical phenotype, immunopathogenesis, cancer immunotherapy
- MeSH terms
- Immune Checkpoint Inhibitors, Humans, Kidney, Nephritis, Interstitial, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
